GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Camlin Fine Sciences Ltd

Camlin Fine Sciences: Q2 FY27 Loss at (Rs. 633.24) Million; Rights Issue Approved

RESULTS ▼ Concern Flagged HIGH RISK
📅 Filed on BSE: 03 Nov 2026, 03:41 PM IST  ·  BSE ID: 1d0eb0e1-2d6c-4672-8562-f43333c0499d
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported a larger loss this quarter and plans to raise up to Rs. 250 crores from shareholders through a Rights Issue.
🤖 AI Summary
  • Camlin Fine Sciences reported a consolidated net loss of (Rs. 633.24) Million for Q2 FY27, compared to a loss of (Rs. 149.50) Million in Q2 FY26.
  • Consolidated total income from operations for Q2 FY27 stood at 4,961.44 Million, a decrease from 5,129.18 Million in Q2 FY26.
  • The Board approved a fundraise via Rights Issue of equity shares, not exceeding Rs. 250 crores, subject to regulatory approvals.
  • SEBI issued an administrative warning letter to the company for violations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
  • The company's shareholding in Vinpai S.A. increased to 94.82% after acquiring 501,842 equity shares for Rs. 200.90 Million in an open offer.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Total Income from Operations (Q2 FY27)
4,961.44 Million
-3.27%
Consolidated Profit/(Loss) for the period (Q2 FY27)
(633.24) Million
Not comparable — astronomical growth rates from startup periods are not real business metrics.
Rights Issue Fundraise Limit
Rs. 250 crores
Shareholding in Vinpai S.A. (post-acquisition)
94.82%
🏢 How This Affects the Company
📈
Business Impact
Consolidated total income from operations decreased, indicating a contraction in core business activity during Q2 FY27.
💰
Financial Impact
The increased net loss and approval for a Rights Issue suggest a need for capital, impacting potential earnings per share due to equity dilution from the Rights Issue.
⚙️
Operational Impact
The increased shareholding in Vinpai S.A. to 94.82% consolidates control over this subsidiary, potentially streamlining its operations within Camlin Fine Sciences.
⚠️
Risk Impact
Receiving an administrative warning letter from SEBI flags compliance adherence risks, while the Rights Issue introduces dilution risk for existing shareholders not participating.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will need to decide whether to participate in the Rights Issue once detailed terms, including the record date, issue price, and ratio, are announced.
👤
Who Is Affected
Existing equity shareholders will be affected by the Rights Issue, as their proportionate ownership may be diluted if they do not participate. All shareholders are affected by the company's financial results.
🔍
Management Signal
The decision to pursue a Rights Issue indicates management's intent to strengthen the company's capital base, despite recent operational losses and regulatory compliance issues.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Announcement of Rights Issue terms, including record date and issue price.
Q3 FY27 financial results to assess ongoing profitability and operational trends.
Any further disclosures regarding SEBI's administrative warning letter or compliance actions.
HIGH RISK Significant increase in net loss, decreased revenue, and a SEBI administrative warning indicate elevated financial and regulatory risks.
💡 Investor Takeaway
Camlin Fine Sciences reported a consolidated net loss of (Rs. 633.24) Million in Q2 FY27, a significant increase from (Rs. 149.50) Million in Q2 FY26. The Board approved a Rights Issue to raise up to Rs. 250 crores and also noted a SEBI administrative warning letter.
⚖️ Strengths & Concerns

✅ Positives

  • Increased control over Vinpai S.A. to 94.82% through an open offer, acquiring 501,842 equity shares for Rs. 200.90 Million.
  • Proactive measure to raise funds up to Rs. 250 crores through a Rights Issue, addressing capital requirements.

⚠️ Concerns

  • Consolidated net loss widened to (Rs. 633.24) Million in Q2 FY27 from (Rs. 149.50) Million in Q2 FY26.
  • Consolidated total income from operations decreased by 3.27% to 4,961.44 Million in Q2 FY27 from 5,129.18 Million in Q2 FY26.
📅 Company Track Record
In FY26, Camlin Fine Sciences reported a consolidated total income of Rs. 175,210.04 Lakh and a profit decline to (Rs. 3,153.10) Lakh. The current Q2 FY27 results show a continued trend of losses.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Camlin Fine Sciences' consolidated net profit or loss in Q2 FY27?
Camlin Fine Sciences reported a consolidated net loss of (Rs. 633.24) Million for the quarter ended September 30, 2026 (Q2 FY27).
What was Camlin Fine Sciences' total consolidated income from operations in Q2 FY27?
The consolidated total income from operations for Camlin Fine Sciences in Q2 FY27 was 4,961.44 Million, down from 5,129.18 Million in Q2 FY26.
What fundraising plan did Camlin Fine Sciences' Board approve?
The Board approved raising funds by way of a Rights Issue of equity shares for an amount not exceeding Rs. 250 crores.
Did SEBI take any action against Camlin Fine Sciences?
Yes, SEBI issued an administrative warning letter to Camlin Fine Sciences for violation of provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
What is Camlin Fine Sciences' current shareholding in Vinpai S.A.?
Following an open offer, Camlin Fine Sciences' shareholding in Vinpai S.A. increased to 94.82%, after acquiring 501,842 equity shares for Rs. 200.90 Million.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.